Engaging biotechnology companies in the development of innovative solutions for diseases of poverty

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Nature reviews. Drug discovery

• Publication date

  2004-02-01

• Fields of study

  Medicine, Business, Economics, Environmental Science

• Identifiers
  DOI 10.1038/nrd1308PMID 15040580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships

  2003cited by this paper
• Genome sequence of the human malaria parasite Plasmodium falciparum

  2002cited by this paper
• Top ten biotechnologies for improving health in developing countries

  2002cited by this paper

• Leishmaniasis: Recent epidemiological studies in the Middle East

  2023cites this paper
• The COVID‐19 pandemic and long‐term incentives for developing vaccines: Patent law under stress

  2022cites this paper
• Poverty Mitigation and Biotechnology

  2021cites this paper
• [Preface for special issue on bioengineering and human health (2019)].

  2019cites this paper
• Clinical bacteriology in low-resource settings: today's solutions.

  2018cites this paper
• Could age and aging change the host response to systemic parasitic infections? A systematic review of preclinical evidence

  2018cites this paper
• Alma Ata and primary healthcare: back to the future

  2018cites this paper
• New alkenyl derivative from Piper malacophyllum and analogues: Antiparasitic activity against Trypanosoma cruzi and Leishmania infantum

  2017cites this paper
• Treatment for Dementia: Learning from Breakthroughs for Other Conditions.

  2016cites this paper
• Gibbilimbol analogues as antiparasitic agents--Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum.

  2016cites this paper
• Antitrypanosomal Acetylene Fatty Acid Derivatives from the Seeds of Porcelia macrocarpa (Annonaceae)

  2015cites this paper
• Lead Identification to Clinical Candidate Selection

  2015cites this paper
• Informatics for neglected diseases collaborations.

  2010cites this paper
• Intellectual Property and Developing Countries

  2010cites this paper
• A review of the literature

  2009cites this paper
• Orphan drug legislation: lessons for neglected tropical diseases.

  2009cites this paper
• Partnerships for vaccine development: building capacity to strengthen developing country health and innovation

  2008cites this paper
• The Indian and Chinese health biotechnology industries: potential champions of global health?

  2008cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• A journey of hope: lessons learned from studies on rare diseases and orphan drugs

  2006cites this paper
• Developing drugs for developing countries.

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Creating Markets for Vaccines

  2006cites this paper
• Opportunities and Challenges in Antiparasitic Drug Discovery

  2005cites this paper
• Priority medicines for Europe and the world

  2004cites this paper
• Strategies to facilitate the development of new contraceptives

  2004cites this paper